BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company’s first proprietary plasmid DNA manufacturing facility in Marburg, Germany. Plasmid […]
10 January 2023 Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial […]
Merck announced the closing of the transaction to acquire M Chemicals Inc., the company recently incorporated by Mecaro Co. Ltd. to operate its chemical business. […]
Merck has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”. Merck, a leading science and technology […]
Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae), a global healthcare company, announced on 5th that its “Envlo 0.3mg”, a new sodium-glucose cotransporters 2 inhibitor (SGLT2) […]
Ad hoc announcement pursuant to Art. 53 LR Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a […]
…to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU, “Ryvu”), a clinical-stage company developing […]
Medical technology company Scivita Medical Technology Co., Ltd. (“Scivita Medical”) looks back on an exciting week at the trade fair. Scivita Medical was able to […]
• Responds to growing global demand for biosafety testing as essential requirement for drug development and commercialization • Expansion creates more than 500 new jobs […]
– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients –– Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with […]
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval Following our communication last week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased to make […]
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder […]
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022. BioNTech invites […]
Copyright © 2023 | WordPress Theme by MH Themes
